<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy and safety of a combination regimen using <z:chebi fb="0" ids="3489">cefmetazole</z:chebi> (<z:chebi fb="1" ids="3490">CMZ</z:chebi>) and <z:chebi fb="0" ids="7528">netilmicin</z:chebi> (NTL) were evaluated in the treatment of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> complicated with <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">Primary diseases</z:e> in 31 patients included in the evaluation were <z:hpo ids='HP_0004808'>acute myelocytic leukemia</z:hpo> (3 cases), <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (2 cases), malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (14 cases), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (2 cases), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> (4 cases), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (2 cases), <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (3 cases), and malignant <z:mpath ids='MPATH_146,MPATH_652'>histiocytosis</z:mpath> (1 case) </plain></SENT>
<SENT sid="2" pm="."><plain>Complicated <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> included 29 cases of suspected <z:mpath ids='MPATH_681'>septicemia</z:mpath>, 1 case of <z:mpath ids='MPATH_681'>septicemia</z:mpath> and 1 case of <z:hpo ids='HP_0002090'>pneumonia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical responses were excellent in 6 (19.4%), good in 12 (38.7%), fair in 1 (3.2%) and poor in 12 (38.7%) </plain></SENT>
<SENT sid="4" pm="."><plain>The total clinical efficacy rate was 58.1% </plain></SENT>
<SENT sid="5" pm="."><plain>No significant effect of initial neutrophil counts was observed on response rates </plain></SENT>
<SENT sid="6" pm="."><plain>Patients who showed increasing neutrophil counts during therapy had higher response rates than those in whom the neutrophil count decreased or remained unchanged at levels less than 500/mm3 in after neutrophil counts </plain></SENT>
<SENT sid="7" pm="."><plain>No side effects were observed in any of the 31 patients </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, this combination therapy of <z:chebi fb="1" ids="3490">CMZ</z:chebi> and NTL thus appears to be useful and safe in therapies for <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> complicated with <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> </plain></SENT>
</text></document>